Advertisement
Advertisement
IBIO
iBio, Inc. Common Stock
1.40
USDSponsored
+0.01
+0.72%
Jul 31, 15:56 UTC -4
Closed
After-Market
1.41
+0.01
+0.36%
IBIO Earnings Reports
Positive Surprise Ratio
IBIO beat 8 of 19 last estimates.
42%
Next Report
Date of Next Report
Sep 03, 2026
Estimate for Q4 26 (Revenue/ EPS)
$58.28K
/-$0.06
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
-70.86%
/-87.76%
iBio, Inc. Common Stock earnings per share and revenue
On May 12, 2026, IBIO reported earnings of -0.06 USD per share (EPS) for Q3 26, beating the estimate of -0.06 USD, resulting in a 6.10% surprise. Revenue reached --, compared to an expected 20.40 thousand, with a -100.00% difference. The market reacted with a -3.73% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 6 analysts forecast an EPS of -0.06 USD, with revenue projected to reach 58.28 thousand USD, implying an increase of 0.00% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Agios Pharmaceuticals, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$1.70
Actual
-$1.69
Surprise
+0.66%
Vericel Corporation
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.02
Actual
$0.04
Surprise
+239.37%
Wave Life Sciences Ltd. Ordinary Shares
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.31
Actual
-$0.34
Surprise
-8.94%
Pharming Group N.V. ADS, each representing 10 ordinary shares
Report Date
Jul 30, 2026 For Q2 26
Estimate
$0.02
Actual
$0.02
Surprise
-0.50%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.25
Actual
$0.00
Surprise
+100.00%
Castle Biosciences, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.41
Actual
-$0.07
Surprise
+83.12%
Myriad Genetics Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.25
Surprise
-323.73%
Bristol-Myers Squibb Co.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.60
Actual
$2.04
Surprise
+27.37%
Moderna, Inc. Common Stock
Report Date
Jul 31, 2026 For Q2 26
Estimate
-$2.12
Actual
-$1.97
Surprise
+7.28%
Guardant Health, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.41
Actual
-$0.42
Surprise
-0.02%
FAQ
What were iBio, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, iBio, Inc. Common Stock reported EPS of -$0.06, beating estimates by 6.1%, and revenue of $0.00, -100% below expectations.
How did the market react to iBio, Inc. Common Stock's Q3 2026 earnings?
The stock price moved down -3.73%, changed from $1.61 before the earnings release to $1.55 the day after.
When is iBio, Inc. Common Stock expected to report next?
The next earning report is scheduled for Sep 03, 2026.
What are the forecasts for iBio, Inc. Common Stock's next earnings report?
Based on 6
analysts, iBio, Inc. Common Stock is expected to report EPS of -$0.06 and revenue of $58.28K for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement